The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Auxilium Pharmaceuticals whiffed on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP loss per share grew.
Margins dropped across the board.
Auxilium Pharmaceuticals booked revenue of $71.0 million. The 13 analysts polled by S&P Capital IQ hoped for sales of $79.5 million on the same basis. GAAP reported sales were 6.4% higher than the prior-year quarter's $66.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.21. The 12 earnings estimates compiled by S&P Capital IQ anticipated -$0.07 per share. GAAP EPS were -$0.21 for Q3 against -$0.08 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 77.7%, 200 basis points worse than the prior-year quarter. Operating margin was -15.1%, 880 basis points worse than the prior-year quarter. Net margin was -14.8%, 870 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $87.2 million. On the bottom line, the average EPS estimate is -$0.06.
Next year's average estimate for revenue is $322.5 million. The average EPS estimate is -$0.04.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 123 members out of 178 rating the stock outperform, and 55 members rating it underperform. Among 50 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 24 give Auxilium Pharmaceuticals a green thumbs-up, and 26 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Auxilium Pharmaceuticals is outperform, with an average price target of $26.18.
- Add Auxilium Pharmaceuticals to My Watchlist.